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Background: The number of elderly (≥75 years) patients with end-stage renal disease (ESRD) has increased
markedly, including in the Limousin region, which has the oldest population in France. We retrospectively
compared outcomes in elderly and non-elderly ESRD patients who started dialysis during two time periods.
Methods: Baseline clinical characteristics, care, and survival rates were assessed in 557 ESRD patients aged ≥75
and <75 years who started dialysis in 2002–2004 and 2005–2007. Survival curves and Cox proportional hazards
model were used to assess survival and factors associated with survival.
Results: Of the 557 patients, 343 and 214 were <75 years and ≥75 years, respectively. Dialysis was started in
2002–2004 and 2005–2007 by 197 and 146 patients <75 years, respectively, and by 96 and 118 patients ≥75 years,
respectively. Median age (73.4 years [interquartile range [IQR] 61.7-79.5 years] vs 69.5 years [IQR 57.4-77.4 years] p = 0.001)
and the proportion aged ≥75 years (44.7% vs 32.8%, p = 0.004) were significantly higher in 2005–2007 than in
2002–2004. Improved initial status during 2005–2007 was observed only in patients ≥75 years, with a decrease in
some co-morbidities, improved walking and better preparation for dialysis. Mortality rates were significantly
lower in 2005–2007 than in 2002–2004 (hazard ratio 0.81, 95% confidence interval 0.69-0.95; p = 0.008), with the
difference due to factors associated with clinical status and care.
Conclusions: Improved initial clinical status and better preparation for dialysis, accompanied by increased
survival, were observed for patients ≥75 years who started dialysis more recently, perhaps because of early
referral to a nephrologist.
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Over the past 10 years, all countries in Europe have ex-
perienced increases in the rate of elderly people begin-
ning dialysis [1,2]. For example, 37.9% of patients in
France who started dialysis in 2009 were older than
75 years [3]. Identifying the characteristics of this elderly
population is important in adapting policies for appro-
priate care and in estimating future needs by renal care
organisation. The higher incidence of end-stage renal
disease (ESRD) may be due in large part to the ageing of
the general population and the broader access to dialysis* Correspondence: florence.glaudet@unilim.fr
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reproduction in any medium, provided the ortherapy among older persons with renal failure [4,5].
Multivariate analysis has shown that increasing age is
significantly predictive of survival in elderly patients on
dialysis [6-9]. Other studies have shown that the excess
mortality observed in people on dialysis compared with
the general population was less apparent in older than in
younger patients [10,11].
Limited data are available on age-related differences in
the clinical status of patients on dialysis and their trends
over time. A study comparing differences between coun-
tries in haemodialysis patients according to age observed
country-related differences in management practices of
elderly individuals, but did not assess changes in man-
agement practices over time [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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registry, which provides quality controlled data about
patients with ESRD. In 2010, 44.3% of individuals on
dialysis in Limousin were over 75 years old, compared
with 39.2% of individuals throughout the rest of France.
To assess the impacts of age and management prac-
tices over time in patients with ESRD, we analysed the
baseline clinical characteristics and care of all patients,
aged <75 and ≥75 years, who started dialysis between
in 2002–2004 and 2005–2007. Survival on dialysis was
compared in patients who started dialysis in these two
time periods, and factors associated with improved survival
in elderly patients were analysed.
Methods
Population
The population of Limousin consisted of 718,716 resi-
dents in 2002 and 737,001 in 2007. All patients living in
the Limousin region and who had started long-term dia-
lysis between January 1, 2002, and December 31, 2007
were included in the study. These 557 patients were
divided into four groups, by age (<75 and ≥75 years) and
period starting dialysis (2002–2004 and 2005–2007). Treat-
ment modalities for haemodialysis included three haemodi-
alysis centres located in health facilities with physicians
always available (in-centre haemodialysis), three haemodi-
alysis centres without a physician always available (out-
centre haemodialysis), three self-care units and home
haemodialysis. Peritoneal dialysis (PD) was either continu-
ous ambulatory or automated.
Data source
The REIN design has been described in detail [13]. The
data included in this study were released from the REIN
registry data under the responsibility of the authors, and
with the approval of the Regional Committee in Limousin.
Data gathered for this study included patient demograph-
ics, co-morbidities, severe disability, mobility, nutritional
status, renal function, anaemia status, and dialysis modal-
ity. Primary renal diseases and renal biopsy before dialysis
were included. The eight co-morbidities assessed were
diabetes, chronic respiratory disease, heart failure, cerebro-
vascular disease, peripheral vascular disease, arrhythmia,
coronary vascular disease and active malignancy. The two
vascular risk factors analysed were hypertension and
smoker/ex-smoker.
Handicaps included severe disabilities (severely im-
paired vision, amputation, hemiplegia and paraplegia)
and severe behavioural disorders (dementia, psychosis,
and severe neurosis that may affect patient dependence
or compliance with treatment). Mobility was classified
into three groups according to patient dependence.
Serum albumin concentrations were measured and body
mass index (BMI) was calculated as weight (kg)/square ofheight (m). Data on mobility and BMI were missing
for <5% of patients.
An urgent first dialysis was defined as its immediate
performance after evaluation by a nephrologist due to
risk of vital status, poorly tolerated anaemia, pericarditis
or uremic confusion of origin.
Renal function was assessed as estimated glomerular
filtration rate (eGFR), which was calculated using the
modification of diet in renal disease (MDRD) formula.
Pre-dialysis anaemia and first treatment modalities were
also determined.
Outcome
All patients were monitored for 4 years after their first
dialysis. Major events included renal transplantation,
changes in place of dialysis, transient recovery of renal
function and death. Vital status was checked monthly,
so that event records can be considered exhaustive.
Statistical analysis
The annual incidence rates were age-standardized using
as reference the estimate of the metropolitan French
population for each year considered.
The impact of demographic factors, age structure and
renal disease risk on ESRD incidence was analysed using
the RiskDiff web tool [14], established as described [15].
Patients’ baseline characteristics were compared using
the chi-square test and Student’s t-test.
In analysing survival, patients were censored if they
underwent renal transplantation during the follow-up
period or were still alive and on dialysis at the end of
follow-up. The chi-square test was used to compare the
proportion of deaths four years after the start of dialysis.
Four-year survival analysis consisted of three steps. First,
the Kaplan-Meier method was used to estimate patient
survival by stratum (age group and study period), with
survival curves compared using log rank tests. Age groups
showing significantly different mortality outcomes during
the two treatment times were analysed for factors asso-
ciated with this difference. Thus, in the second step for
this group, a Cox proportional hazard model was used
to analyse risk factors associated with death during the
first 48 months (univariate analysis), regardless of the
dialysis initiation period. Finally, in order to analyse
the association between study period and mortality, five
Cox proportional hazard models were fitted with sequen-
tial adjustments for confounding variables (multivariate
analysis). Model-1 was adjusted for age and gender;
Model-2 was Model-1 plus adjustments for co-morbidities
associated with survival during the previous step; Model-3
was Model-1 plus adjustments for mobility; model-4 was
Model-1 plus adjustments for initial condition at the start
of dialysis; and Model 5 included all variables used in the
other models.
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[CIs] were calculated. All data were analysed using JMP




During the study period, 557 patients underwent dialy-
sis, including 293 in 2002–2004 and 264 in 2005–2007.
Of the patients who started dialysis in 2002–2004, 197
were < 75 and 96 were ≥75 years old; In 2005–2007, 146
were <75 and 118 were ≥75 years old. Median age of co-
horts were 69.5 years [IQR 57.4-77.4 years] in 2002–
2004 and 73.4 years [IQR 61.7-79.5 years] in 2005–2007
(p = 0.001). Among the patients ≥75 years old, median
age was 79.9 years [IQR 77.5-82.9 years] in 2002–
2004 and 80.3 years [IQR 77.4-83.3 years] in 2005–2007
(p = NS).
Figure 1 shows the change in incidence by age group.
The older age group showed an increase in incidence of
ESRD between 2003 and 2007, especially after 2006. The
incidence was high (385 per million [IQR 254–516 per
million]) in 2002–2004, but was even higher (437 per
million [IQR 301–573 per million] in 2005–2007). The
incidence of ESRD in patients ≥ 75 years increased from
397 per million [IQR 262–532 per million] in 2002–
2004 to 457 per million [IQR 313–597 per million] in
2005–2007.
Figure 2 shows the real contribution of kidney dis-
ease to the change in ESRD incidence over time, tak-
ing into account changes in the general population
between 2002 and 2007. The increased incidence in
ESRD for patients ≥75 years between 2003 and 2007
was associated with an increase in the proportion of
the elderly population, but primarily to the increase in
kidney disease risk. In the younger population, those
aged <75 years, the decreased incidence of ESRD was
due mainly to a lower risk of kidney disease.
Table 1 shows the baseline characteristics of pa-


































Figure 1 Standardized incidence by age group between 2002
and 2007.cerebrovascular disease, peripheral vascular disease and
arrhythmia were significantly higher in 2005–2007 than in
2002–2004. The percentage of patients aged <44 years was
lower in 2005–2007. When only patients aged 45–74 years
were assessed, there were also significant increases over
time in these three co-morbidities. The first treatment mo-
dality has changed significantly over time, with a decrease
in the number of patients undergoing peritoneal dialysis
and an increase in those undergoing haemodialysis with
fistula (Table 2).
When we assessed patients aged ≥75 years, we observed
no significant difference in co-morbidities over time, al-
though the proportions with diabetes, heart failure and
arrhythmia decreased. The percentage of patients walking
independently was higher in 2005–2007 than in 2002–
2004 (p = 0.002). More biopsies were performed and more
patients on dialysis had a serum albumin concentra-
tion ≥35 g/l during 2005–2007. The proportions of pa-
tients on dialysis with a baseline eGFR < 10 ml/min/
1.73 m2 and with haemoglobin concentrations <11 g/dl
were significantly higher during the second period.
The interaction between age and study period was
tested for all baseline characteristics (p3 of Table 1). This
interaction was significant for renal biopsy, arrhythmia,
and haemoglobin concentrations.
Patient survival
After 4 years of follow-up, 79 (82.3%) and 77 (65.2%)
patients aged ≥75 years died in 2002–2004 and 2005–
2007, respectively (p = 0.033). Only one underwent
renal transplantation during follow-up. Among patients
aged <75 years, 59 (29.9%) and 54 (37.0%) died within
4 years in 2002–2004 and 2005–2007, respectively. Fifty-
eight patients (29.4%) underwent renal transplantation in
2002–2004 and 37 (25.3%) in 2005–2007 (p = 0.378).
The Kaplan-Meier survival curves are shown in Figure 3.
Median survival was stable in the entire cohort (3.7 years
in 2002–2004 and 3.6 years in 2005–2007) and in pa-
tients <75 years old (p = 0.285). In patients aged ≥75 years,
however, median survival was significantly longer in 2005–
2007 than in 2002–2004 (2.6 vs 1.6 years, p = 0.008).
Factors associated with survival in patients ≥75 years
As a survival difference was observed only for patients
aged ≥75 years, we analysed factors potentially involved
in improved survival of this group. Univariate analyses
showed that period of dialysis initiation, primary kidney
disease, diabetes, heart failure, impaired mobility, estimated
glomerular filtration rate (eGFR) and first treatment mo-
dality were significantly associated with mortality.
Patients who started dialysis in 2005–2007 had a 19%
lower risk of dying after 4 years (HR 0.81, CI 95% 0.7-
0.9). Adjustment for co-morbidities resulted in a decreased
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Figure 2 Differences in incidence from 2003 to 2007 compared to the baseline year 2002. Legend of Figure 2: A. <75 years; B. ≥75 years.
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cing mobility (Model 3) or initial treatment condition
(Model 4). Model 5 showed that heart failure, assistance
needed for transfers, PD, and eGFR ≥10 ml/min/1.73 m2
were significantly associated with the better survival ob-
served in 2005–2007 (Table 3).
Discussion
This study showed that the percentage of patients ≥75 years
of age starting dialysis increased and that their initial clin-
ical characteristics improved over time, improvements as-
sociated with significantly longer survival.
Increases in elderly population
Over the past 10 years, the number of elderly pa-
tients starting dialysis has increased in many countries
[1,6,10,16-18]. Our results confirm that the dialysed popu-
lation in Limousin has increased in age. Several methods
of calculation showed that 2002 remained an exception to
the steady increase in the incidence of elderly personsstarting dialysis, suggesting that the higher number of pa-
tients observed was probably due to sample fluctuations.
Many hypotheses have attempted to explain the signifi-
cant increase in the incidence of elderly patients starting
dialysis. The first hypothesis was an increase in the inci-
dence of diabetes [4,5] and the improved survival from
non renal diseases among people with chronic renal insuf-
ficiency [19,20]. Higher eGFR and wider access to dialysis
were shown associated with the dramatic increases in inci-
dence of older patients [18] and of patients of all ages [21]
starting dialysis. We observed no difference in the propor-
tion of patients ≥75 years with eGFR ≥10 ml/min/1.73 m2
in the two time periods, indicating that this factor cannot
explain the increase in ESRD incidence among elderly
people in Limousin. Improved patient care, including early
referral to nephrologists prior to dialysis, may be associated
with the increased incidence of elderly subjects starting
dialysis, by reducing death before ESRD. Indeed, the in-
creased proportions of our patients with fistula before dia-
lysis and better clinical status strengthen this hypothesis.
Table 1 Patient clinical baseline characteristics at dialysis initiation according to age and period
<75 yr ≥75 yr
2002-2004 2005-2007 P1 2002-2004 2005-2007 P2 P3
(n = 197) (n = 146) (n = 96) (n = 118)







85 et + 15(15.6) 19(16.1)
Gender
Men 126(64.0) 100(68.5) 54(56.2) 83(70.3)
Women 71(36.0) 46(31.5) 42(43.7) 35(29.7)
Primary rental disease NS 0.10 NS
Glomerulonephritis 38(19.3) 24(16.4) 9(9.4) 20(16.9)
Diabetic nephropathy 45(22.8) 34(23.3) 19(19.8) 15(12.7)
Cystic nephropathy 14(7.1) 17(11.6) 2(2.1) 2(1.7)
Tubular-Interstitial nephropathy 19(9.6) 12(8.2) 4(4.2) 8(6.8)
Vascular nephropathy 36(18.3) 20(13.7) 37(38.5) 51(43.2)
Unknown 29(14.7) 25(17.1) 23(24.0) 15(12.7)
Other 16(8.1) 14(9.6) 2(2.1) 7(5.9)
Renal biopsy 43(21.8) 31(21.2) NS 4(4.2) 14(11.9) 0.044* 0.047*
Co-morbidities
Diabetes 65(33.0) 54(37.0) NS 39(40.6) 34(28.8) 0.07 0.06
Chronic respiratory disease 15(7.6) 17(11.6) NS 11(11.5) 14(11.9) NS NS
Heart failure 40(20.3) 28(19.2) NS 42(43.7) 37(31.4) 0.06 NS
Cerebrovascular disease 10(5.1) 18(12.3) 0.016* 13(13.5) 16(13.6) NS 0.09
Peripheral vascular disease 28(14.2) 37(25.3) 0.010* 26(27.1) 31(26.3) NS 0.07
Arrhythmia 22(11.2) 31(21.2) 0.011* 29(30.2) 29(24.6) NS 0.015
Coronary vascular disease 40(20.3) 33(22.6) NS 35(36.5) 42(35.6) NS NS
Active malignancy 9(4.6) 12(8.2) NS 7(7.3) 10(8.5) NS NS
Risk factors
History of hypertension 148(75.1) 118(80.8) NS 75(78.1) 101(85.6) NS NS
Smoker/Ex-smoker 71(36.0) 69(47.3) NS 31(32.3) 45(38.1) NS NS
Handicap1 23(11.7) 19(13.0) NS 6(6.2) 9(7.6) NS NS
Mobility NS 0.002* NS
Walk without help 169(88.5) 130(90.9) 57(63.3) 88(75.9)
Need assistance for transfers 15(7.9) 6(4.2) 31(34.4) 18(15.5)
Totally dependent for transfers 7(3.7) 7(4.9) 2(2.2) 10(8.6)
P1. P-value <75 years (2002-2004 vs 2005-2007).
P2. P-value ≥75 years (2002-2004 vs 2005-2007).
P3. P-value Age x Period.
1including severe disability (vision impairment, paraplegia, hemiplegia, and amputation) and severe behaviour disorders (dementia, psychosis or severe neurosis).
NS Not Significant (with p>0.1).
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to patients starting dialysis at a later age, but also to im-
provements in their general condition and a lower eGFR
before starting dialysis. Presumably, some patients whowould not have survived before reaching ESRD would now
survive and be candidates for dialysis.
The urgency of the first dialysis did not differ between
the two time periods, regardless of age, and did not
Table 2 Biological baseline characteristics and conditions of dialysis initiation according to age and period
<75 yr ≥75 yr
2002-2004 2005-2007 P1 2002-2004 2005-2007 P2 P3
(n = 197) (n = 146) (n = 96) (n = 118)
Serum albumin NS 0.027* NS
<35 g/l 63(32.0) 51(34.9) 44(45.8) 50(42.4)
≥35 g/l 78(39.6) 61(41.8) 21(21.9) 44(37.3)
Missing 56(28.4) 34(23.3) 31(32.3) 24(20.3)
Body mass index NS NS NS
<18, 5 kg/m2 9(4.7) 5(3.6) 2(2.3) 7(6.1)
18, 5–25 kg/m2 98(51.0) 67(47.9) 51(60.0) 64(56.1)
≥18,5 kg/m2 85(44.3) 68(48.6) 32(37.6) 43(37.7)
Baseline eGFR NS 0.047* 0.08
<7 ml/min/1.73 m2 103(52,3) 59(40,4) 31(32,3) 46(39,0)
7–10 ml/min/1.73 m2 47(23,9) 46(31,5) 26(27,1) 38(32,2)
≥10 ml/min/1.73 m2 32(16.2) 32(21.9) 28(29.2) 31(26.3)
Missing 15(7.6) 9(6.2) 11(11.5) 3(2.5)
Pre-dialysis anemia care
Hemoglobin NS <0.001* 0.005*
<11 g/dl 112(56.9) 77(52.7) 42(43.7) 74(62.7)
≥11 g/dl 63(32.0) 57(39.0) 3637.5) 41(34.7)
Missing 22(11.2) 12(8.2) 18(18.7) 3(2.5)
Pre-dialysis ESA treatment 93(47.2) 85(57.8) 0.044* 51(53.1) 67(56.8) NS NS
First treatment modality 0.004* NS NS
Peritoneal dialysis 39(19.8) 17(11.6) 35(36.5) 32(27.1)
Hemodialysis with fistula 77(39.1) 74(50.7) 18(18.7) 36(30.5)
Hemodialysis without fistula 81(41.1) 55(37.7) 43(44.8) 50(42.4)
In urgency 39(19.8) 25(17.1) NS 16(16.7) 19(16.1) NS NS
P1. P-value <75 years (2002-2004 vs 2005-2007).
P2. P-value ≥75 years (2002-2004 vs 2005-2007).
P3. P-value Age x Period.
eGFR Estimated glomerular filtration rate, ESA erythropoietin-stimulating agent, NS Not Significant (with p>0.1).
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information on nephrological follow-up prior to the
start of dialysis.
Progression over time
We also observed changes in clinical status and patient
care between the two periods. The percentage of elderly
patients undergoing renal biopsies increased signifi-
cantly, resulting in a decreased in the rate of patients
with indeterminate renal diseases and indicating that the
management of this population changed before the start
of dialysis. There was a correlation between age and the
start of dialysis, indicating an increase in work-ups at
the beginning of dialysis.
Disability among older patients was modified over time,
with older patients having improved autonomy and the
percentage walking without help increasing significantly.
Although nutritional status may difficult to determine only
from measurements of serum albumin concentration, therate of albuminemia decreased, suggesting improvements
in nutritional status and/or inflammatory responses.
This finding is consistent with previous results, which
underlined the importance of monitoring albumin con-
centration [22]. In contrast, pre-dialysis anemia care be-
came worse for patients over time, a finding consistent
with international recommendations of a lower target
haemoglobin concentration, resulting from findings sug-
gesting that administration of high EPO does not reduce
mortality or cardiovascular risk prior to the initiation of
dialysis [23,24].
Although a higher BMI is associated with worsen-
ing co-morbidities in younger Caucasian populations,
this was less evident in older patients [25]. In our study,
this was difficult to determine, inasmuch as only 2 pa-
tients ≥75 years old had a BMI <18.5 kg/m2 in 2002–2004.
The increase in the percentage of patients undergoing
initial haemodialysis with fistula was partly due to a de-




































































2002-2004 293 228 158 125 96
2005-2007 264 209 163 124 94
2002-2004 197 165 116 96 80
2005-2007 146 122 94 74 55
2002-2004 96 66 43 30 16
2005-2007 118 88 70 51 39
Figure 3 Kaplan Meier analysis: 4-year survival according to
the start of dialysis. Legend of Figure 3: A. all patients (n = 557);
B. <75 years (n = 343); C. ≥75 years (n = 214).
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difference was significant only for patients <75 years old.
Survival
The main finding of our study was the improvement in
survival of elderly patients over time. In contrast, there
were no significant differences in the entire cohort or
the younger patient group between the two periods. Age
has been reported to influence survival in dialysed eld-
erly patients [7,18,26], although other studies [10,11,27]
have found that age was not an independent predictor
of survival in elderly patients. A method of predicting
6-month prognosis in elderly patients starting dialysis
found that functional limitations were better predictorsthan age [27]. When this score was applied to our cohort,
the mortality rates were similar to those presented, at
least for groups containing large numbers of patients
(data not shown). Thus, our results were in agreement
with studies showing that neither age nor gender was sig-
nificantly associated with survival among elderly patients.
Moreover, our findings emphasize the importance of
functional limitations in predicting survival. Improved
autonomy, including being able to walk unaided, was sig-
nificantly associated with the increase in survival over
time. Walking has already been found to be strongly as-
sociated with mortality in aged populations, a relation-
ship not altered by dialysis [17,28].
The impact of the method of dialysis on survival is un-
clear. Although studies have analysed the link between
dialysis methods and survival [17,26,29], those studies
were criticized due to the selection bias inherent in the
choice of dialysis method, which could explain apparent
differences in mortality rate [30]. Indeed, peritoneal dia-
lysis is often promoted for patients with diabetes [31],
elderly patients [32] and patients with heart failure [33].
Although this requires further investigation, evaluating
the impact of dialysis method on survival is very diffi-
cult, with the method adjusted for individual patients.
The main limitation of this study was its sample size.
Although Limousin has the highest proportion of people
over 75 years old in France, it is one of the least popu-
lated regions. Thus, some variables with borderline sig-
nificance may be more sensitive to adjustments. Another
limitation was that our study included only ESRD patients
starting dialysis, excluding a small number of patients with
serious ESRD who were treated conservatively and intro-
ducing a selection bias. Following the evolution of this
population over time seems to be important. As in many
regions of France, a system monitoring early renal failure
was recently initiated in Limousin. Nephrological follow up
before dialysis has an impact on quality of life. In the eld-
erly, the quality of life is better when the first dialysis has
been programmed [34]. Finally, we compared patient sur-
vival with data at the initiation of dialysis. Changes in pa-
tient co-morbidities and their care after dialysis initiation
were not considered.
This study also has several strengths. The small num-
ber of nephrologists and their involvement during the
pilot phase of the registry ensured stability in coding and
completeness and resulted in rigorous patient follow up.
Thus, our cohort was not subject to the bias frequently
observed in larger cohorts, due to the exclusion of pa-
tients with missing data or difficult compilation from
various sources of information.
Conclusions
In conclusion, we observe an increase over time in the
incidence of elderly patients starting dialysis, as well as a
Table 3 Adjusted hazard ratios of overall, 4-year mortality associated with study period (for all 214 patients over 75 years)
Model-1 Mdel-2 Model-3 Model-4 Model-5
Demographics Demographics + Comorbidity Demographics +Mobility Demographics + Care 1 + 2 + 3 + 4
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Dialysis initiation year. reference: 2002-2004
2005-2007 0.81 0.69-0.95 0.010* 0.85 0.72-0,999 0.049* 0.88 0.74-1.06 NS 0.85 0.72-1.00 0.052 0.94 0.78-1.13 NS
Age. reference: 75–84 years
≥85 years 1.22 0.99-1.48 0.06 1.27 1.03-1.54 0.027* 1.18 0.95-1.44 NS 1.20 0.97-1.46 0.09 1.21 0.97-1.48 0.09
Gender. reference: Male
Female 0.99 0.84-1.17 NS 1.00 0.84-1.18 NS 0.95 0.80-1.13 NS 0.97 0.81-1.15 NS 0.96 0.80-1.15 NS
Comobidities. reference: without this comorbidity
Heart failure 1.31 1.11-1.55 0.001* 1.23 1.04-1.46 0.018*
Diabetes 1.21 1.02-1.43 0.030* 1.12 0.94-1.93 0.10
Mobility. reference: walk out help
Need assistance for transfers 1.43 1.16-1.74 <0.001* 1.40 1.13-1.71 0.002*
Tatally dependent for transfers 1.42 0.97-1.96 0.07 1.38 0.94-1.93 0.10
Dailysis modality. reference: HD with fistula
HD without fistula 1.29 1.03-1.62 0.025* 1.16 0.92-1.48 NS
PD 1.49 1.19-1.89 <0.001* 1.38 1.09-1.76 0.008*
Baseline eGFR. reference: 7≥ eGFR < 10 ml/min/1.73 m2
eGFR < 7 ml/min/1.73 m2 1.08 0.88-1.33 NS 1.18 0.95-1.46 NS
eGFR ≥ 10 ml/min/1.73 m2 1.25 1.00-1.56 0.047* 1.36 1.08-1.71 0.009
Missing 1.13 0.79-1.55 NS 1.12 0.77-1.57 NS
HD hemodialysis, PD peritoneal dialysis, eGFR estimated glomerular filtration rate, HR hazard ratio, 95% CI 95% confidence intervals.
Model-1 was adjusted for age and gender.
Model-2 was adjusted as Model-1 + heart failure and diabetes.
Model-3 was adjusted as Model-1 +mobility.
Model-4 was adjusted as Model-1 + dialysis modality and baseline eGFR.
Model-5 was adjusted for all variables in previous models.
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http://www.biomedcentral.com/1471-2369/14/131decrease in the differences between younger and elderly
patients. Both of these findings may be due to global im-
provements in the health status of elderly individuals.
The decrease in some co-morbidities and improvements
in functional limitations were associated with signifi-
cantly improved survival among patients ≥75 years. Our
findings suggest that older individuals are better man-
aged during the progression of chronic kidney disease, a
finding requiring confirmed in other cohorts of patients
with chronic kidney disease.
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